Published in Genomic Psychiatry · View the paper (DOI)
Researchers at Flinders University discover a genetic mutation that silences a brain receptor, rendering it unresponsive to both natural trace amines and clinical drug candidates. The C182F variant eliminates receptor signaling and reduces cell surface expression, with profound implications for emerging psychiatric treatments.
Coverage from 2 institutions